share_log

港股异动丨沛嘉医疗-B涨超3%创年内新高 去年收入同比增约38.3%-42.8%

Hong Kong stocks are moving丨PEIJIA-B rose more than 3% to set a new high for the year, with last year's revenue increasing by approximately 38.3%-42.8% year-on-year.

Gelonghui Finance ·  Feb 11 08:05

Gelonghui, February 11 | PEIJIA-B (9996.HK) saw an intraday increase of 3.25% to 4.13 Hong Kong dollars today, marking a new high for the year. PEIJIA announced last night that for the year ending December 31, 2024, the company's revenue is expected to be approximately RMB 0.61 billion to 0.63 billion, representing a year-on-year increase of about 38.3% to 42.8%. The strong revenue growth is mainly attributed to: (i) the continuous rapid growth of all the group's neurointervention product lines; and (ii) the expansion of the group's market share in the transcatheter aortic valve replacement ("TAVR") market in China. During the reporting period, significant revenue growth was achieved in the hemorrhagic, ischemic, and access neurointervention product lines due to increased surgical penetration rates, winning bids in volume-based procurement, and a comprehensive product pipeline along with effective marketing strategies. (Gelonghui)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 390

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.